MedPath

Efficacy of Lyophilized Dried Cornus Mas L. on Anthropometric and Biochemical Parameters in Insulin Resistance

Not Applicable
Completed
Conditions
Insulin Resistance
PreDiabetes
Obesity
Interventions
Dietary Supplement: Cornelian Cherry (Cornus mas L.)
Behavioral: Diet
Registration Number
NCT05292300
Lead Sponsor
Marmara University
Brief Summary

The aim of this study is to determine the effect of 3 months supplementation of lyophilize dried cornelian cherry (Cornus mas L.) on women diagnosed with insulin resistance. The baseline and end biochemical parameters and anthropometric measurements will be compared with control subjects.

Detailed Description

The main purpose of this study is to determine the efficacy of the lyophilizer-dried powder form of cornelian cherry (Cornus mas L.) grown in our country on inflammation in women with insulin resistance by biochemical parameters.

Sub-objectives of the study;

* Determining the presence of inflammation in women with insulin resistance.

* Determination of the effect of cornelian cherry on both fasting blood glucose, insulin and blood lipid profile.

* Determination of both anti-inflammatory, antidiabetic and antioxidant effects of cornelian cherry.

* Determination of the effect of cornelian cherry on anthropometric measurements.

The aim of this study is to compare the anthropometric measurements and biomarkers of women with insulin resistance as a result of the consumption of powdered cornelian cherry (Cornus mas L.) that has been freeze-dried at -55 degrees with a Lyophilizer device for 12 weeks.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
84
Inclusion Criteria
  • Women aged between 18 and 45 years with insulin resistance.
  • Those who have not experienced menopause
  • Those who applied to the obesity clinic
  • Volunteers
  • Those who signed the consent form
Exclusion Criteria
  • Those who use medicine for diabetes and thyroid diseases,
  • Those taking hormone therapy
  • Pregnant and lactating women
  • Those with a history of cancer
  • Patients with communication problems.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Cornelian Cherry and Diet GroupDietAmong those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet and will receive 20 g/day Cornelian Cherry powder for their one portion fruit a day.
Diet GroupDietAmong those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet.
Cornelian Cherry GroupCornelian Cherry (Cornus mas L.)Among those who applied to the clinic, those who do not want to follow their diet will be randomized into this group. Patients in this group will receive 20 g/day Cornelian Cherry powder.
Cornelian Cherry and Diet GroupCornelian Cherry (Cornus mas L.)Among those who applied to the clinic, those who want to follow their diet will be randomized into this group. Patients in this group will be followed by a personalized diet and will receive 20 g/day Cornelian Cherry powder for their one portion fruit a day.
Primary Outcome Measures
NameTimeMethod
Change from Baseline in the Fasting Blood Glucose (mg/dl) at 12 weeks3 months

The fasting blood glucose (mg/dl) at the baseline and 12 weeks later will be taken noted from the routinely requested tests in the hospital. These values will be recorded for all groups; Control Group, the Diet Group (who received a diet for 3 months), Cornelian Cherry and Diet Group (who received additional 20 g/day of dried powdered Cornelian Cherry with their diet), Cornelian Cherry Group (who was given only 20 g/day of dried powdered Cornelian Cherry ).

Change from Baseline in the Fasting Insulin (mU/L) at 12 weeks3 months

The fasting insulin (mU/L) values of the women with insulin resistance at the baseline and 12 weeks later will be taken noted from the routinely requested tests in the hospital. These values will be recorded for all groups; Control Group, the Diet Group (who received a diet for 3 months), Cornelian Cherry and Diet Group (who received additional 20 g/day of dried powdered Cornelian Cherry with their diet), Cornelian Cherry Group (who was given only 20 g/day of dried powdered Cornelian Cherry ).

Change from Baseline in the BMI (kg/m2)3 months

The body weight (kg) and height (m) of the women with insulin resistance at the baseline, 4 weeks, 8 weeks and 12 weeks will be taken by the researcher and noted in their files.

The height of the patients will be measured with a fixed height meter with 0.5 cm intervals, with shoes off.

For body analysis, an 8-electrode bioelectrical impedance (BIA) device Tanita MC 780 MA, which performs segmental analysis, will be used. Patients will be asked to remove all metal items (rings, earrings, bracelets, watches, phones, etc.), any heavy clothing, shoes, and socks before stepping on the device. The device is set to -1.0 kg for the remaining clothes.

From these measurements, body weight, body fat (kg), body fat percentage (%), body muscle (kg) and body water (kg) values will be recorded. Body mass index (BMI) will be calculated as weight (kg) divided by height (m) squared.

Change from Baseline in the HOMA-IR at 12 weeks3 months

The fasting blood glucose (mg/dl) and fasting insulin (mU/L) values of the women with insulin resistance at the baseline and 12 weeks later will be taken noted from the routinely requested tests in the hospital. HOMA-IR will be calculated with the formula (fasting glucose (mg/dl) x fasting insulin (mU/L)) / 405. These values will be recorded for all groups; Control Group, the Diet Group (who received a diet for 3 months), Cornelian Cherry and Diet Group (who received additional 20 g/day of dried powdered Cornelian Cherry with their diet), Cornelian Cherry Group (who was given only 20 g/day of dried powdered Cornelian Cherry ).

Change from Baseline in the Anthropometric Measurements3 months

The anthropometric measurements of the women with insulin resistance at the baseline, 4, 8 and 12 weeks will be taken by the researcher. These measurements are; waist circumference(cm), hip circumference(cm), mid-upper arm circumference(cm), neck circumference(cm), waist to height ratio(cm) and waist to hip ratio(cm). Waist circumference will be measured using an inflexible tape at the umbilicus level after normal exhalation to the nearest 0-1 cm. Hip circumference will be measured from the widest area between the waist and the thigh. The waist-to-hip will be calculated from the formula waist(cm)/hip(cm) and waist-to-height ratios will be calculated from the formula waist(cm)/height(cm). Middle-upper arm circumference will be measured on the left arm of the patients. Neck circumference will be measured with the shoulders in the free position from the point where the thyroid cartilage is most protruding.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Marmara University

🇹🇷

Istanbul, Maltepe, Turkey

© Copyright 2025. All Rights Reserved by MedPath